Panbela Therapeutics Statistics
Total Valuation
PBLA has a market cap or net worth of $1.65 million. The enterprise value is $5.58 million.
| Market Cap | 1.65M |
| Enterprise Value | 5.58M |
Important Dates
The last earnings date was Thursday, May 2, 2024, after market close.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PBLA has 4.85 million shares outstanding. The number of shares has increased by 23,880.32% in one year.
| Shares Outstanding | 4.85M |
| Shares Change (YoY) | +23,880.32% |
| Shares Change (QoQ) | -98.68% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | n/a |
| Float | 4.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.17
| Current Ratio | 0.17 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -258.93% |
| Return on Capital (ROIC) | -3,505.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.41M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -323,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.22% in the last 52 weeks. The beta is 0.92, so PBLA's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -99.22% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 6.09 |
| Relative Strength Index (RSI) | 40.00 |
| Average Volume (20 Days) | 16,024 |
Short Selling Information
The latest short interest is 106,974, so 2.20% of the outstanding shares have been sold short.
| Short Interest | 106,974 |
| Short Previous Month | 177,730 |
| Short % of Shares Out | 2.20% |
| Short % of Float | 2.20% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | -27.50M |
| Operating Income | -35.34M |
| Pretax Income | -27.58M |
| Net Income | -27.26M |
| EBITDA | -35.22M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -$215.14 |
Balance Sheet
The company has $262,000 in cash and $4.19 million in debt, giving a net cash position of -$3.93 million or -$0.81 per share.
| Cash & Cash Equivalents | 262,000 |
| Total Debt | 4.19M |
| Net Cash | -3.93M |
| Net Cash Per Share | -$0.81 |
| Equity (Book Value) | -3.19M |
| Book Value Per Share | -0.66 |
| Working Capital | -8.73M |
Cash Flow
| Operating Cash Flow | -24.89M |
| Capital Expenditures | n/a |
| Free Cash Flow | -24.89M |
| FCF Per Share | -$7.96 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PBLA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23,880.32% |
| Shareholder Yield | -23,880.32% |
| Earnings Yield | -1,650.38% |
| FCF Yield | -1,507.00% |
Analyst Forecast
The average price target for PBLA is $25.00, which is 7,248.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.00 |
| Price Target Difference | 7,248.62% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 18, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 18, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |